Evidence map›Paper›PMID 32372956›Full record

ArticleFrontiers in pharmacology2020

Danqi Pill Protects Against Heart Failure Post-Acute Myocardial Infarction

Qian Zhang, Dongqing Guo, Yuanyuan Wang, Xiaoping Wang, Qiyan Wang, Yan Wu, Chun Li, Wei Wang, Yong Wang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Benzoylaconine improves mitochondrial function in oxygen-glucose deprivation and reperfusion-induced cardiomyocyte injury by activation of the AMPK/PGC-1 axis.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2022
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Qian ZhangSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Dongqing GuoThe School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
Yuanyuan WangSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Xiaoping WangThe School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
Qiyan WangThe School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
Yan WuInstitute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Chun LiModern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Wei WangSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Yong WangSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Beijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimHeart failure (HF) post-acute myocardial infarction (AMI) leads to a large number of hospitalizations and deaths worldwide. Danqi pill (DQP) is included in the 2015 national pharmacopoeia and widely applied in the treatment of HF in clinics in China. We examined whether DQP acted on glucose metabolism to protect against HF post-AMI METHODS AND

resultsIn this study, left anterior descending (LAD) artery ligation induced HF post-AMI rats and oxygen-glucose deprivation-reperfusion (OGD/R)-induced H9C2 cell model were structured to explore the efficacy and mechanism of DQP. Here we showed that DQP protected the heart against ischemic damage as evidenced by improved cardiac functions and attenuated inflammatory infiltration. The expressions of critical proteins involved in glucose intake and transportation such as GLUT4 and PKM2 were up-regulated, while negative regulatory proteins involved in oxidative phosphorylation were attenuated in the treatment of DQP. Moreover, DQP up-regulated NRF1 and TFAM, promoted mitochondrial biogenesis and increased myocardial adenosine triphosphate (ATP) level. The protection effects of DQP were significantly compromised by HIF-1α siRNA, suggesting that HIF-1α signaling pathway was the potential target of DQP on HF post-AMI.

conclusionsDQP exhibits the efficacy to improve myocardial glucose metabolism, mitochondrial oxidative phosphorylation and biogenesis by regulating HIF-1α/PGC-1α signaling pathway in HF post-AMI rats.

Indexed as

acute myocardial infarction (AMI)Danqi Pill (DQP)glucose metabolismheart failure (HF)HIF-1α/PGC-1α pathway

Identifiers

PMID32372956
PMCPMC7187888
OpenAlexW3018220382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.